Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gustavo Grampp

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 20, 2015
The Diversity of Biosimilar Design and Development: Implications for Policies and StakeholdersGustavo Grampp, Sundar Ramanan
Expert Review of Clinical Pharmacology|January 7, 2014
Preventing shortages of biologic medicinesSundar Ramanan, Gustavo Grampp
Nephrology News & Issues|December 19, 2015
Study design is important for ESA biosimilarsAllan Pollock, Gustavo Grampp
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 1, 2015
Pharmacovigilance Considerations for Biosimilars in the USAGustavo Grampp, Thomas Felix
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2014
Drift, evolution, and divergence in biologics and biosimilars manufacturingSundar Ramanan, Gustavo Grampp
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 27, 2013
Managing unexpected events in the manufacturing of biologic medicinesGustavo Grampp, Sundar Ramanan
Current Medical Research and Opinion|April 24, 2012
Comparability and biosimilarity: considerations for the healthcare providerJaymi F Lee, Jason B Litten, Gustavo Grampp
Mabs|April 23, 2011
Biosimilars 2.0: guiding principles for a global "patients first" standardJoseph Miletich, Geoffrey Eich, Gustavo Grampp, et al.
Biologicals : Journal of the International Association of Biological Standardization|November 1, 2019
Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case studyRobin Thorpe, Gustavo Grampp, Hye-Na Kang, et al.
Journal of Pharmaceutical Sciences|February 7, 2018
Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study DesignsGustavo Grampp, Patricia L McElroy, Gary Camblin, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 20, 2015
The Diversity of Biosimilar Design and Development: Implications for Policies and StakeholdersGustavo Grampp, Sundar Ramanan
Expert Review of Clinical Pharmacology|January 7, 2014
Preventing shortages of biologic medicinesSundar Ramanan, Gustavo Grampp
Nephrology News & Issues|December 19, 2015
Study design is important for ESA biosimilarsAllan Pollock, Gustavo Grampp
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 1, 2015
Pharmacovigilance Considerations for Biosimilars in the USAGustavo Grampp, Thomas Felix
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2014
Drift, evolution, and divergence in biologics and biosimilars manufacturingSundar Ramanan, Gustavo Grampp
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 27, 2013
Managing unexpected events in the manufacturing of biologic medicinesGustavo Grampp, Sundar Ramanan
Current Medical Research and Opinion|April 24, 2012
Comparability and biosimilarity: considerations for the healthcare providerJaymi F Lee, Jason B Litten, Gustavo Grampp
Mabs|April 23, 2011
Biosimilars 2.0: guiding principles for a global "patients first" standardJoseph Miletich, Geoffrey Eich, Gustavo Grampp, et al.
Biologicals : Journal of the International Association of Biological Standardization|November 1, 2019
Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case studyRobin Thorpe, Gustavo Grampp, Hye-Na Kang, et al.
Journal of Pharmaceutical Sciences|February 7, 2018
Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study DesignsGustavo Grampp, Patricia L McElroy, Gary Camblin, et al.
Pageof 2